Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment

Hanqing Liu; Zhigang Tu; Fan Feng; Haifeng Shi; Keping Chen; Ximing Xu

doi:10.1515/acph-2015-0019

.blurhash-client-img { display: none !important; }

Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment

Acta Pharmaceutica

Volume 65 (2015): Issue 2 (June 2015)

By: Hanqing Liu, Zhigang Tu, Fan Feng, Haifeng Shi, Keping Chen and Ximing Xu

Open Access

|May 2015

Abstract

A virosome is an innovative hybrid drug delivery system with advantages of both viral and non-viral vectors. Studies have shown that a virosome can carry various biologically active molecules, such as nucleic acids, peptides, proteins and small organic molecules. Targeted drug delivery using virosome-based systems can be achieved through surface modifications of virosomes. A number of virosome- -based prophylactic and therapeutic products with high safety profiles are currently available in the market. Cancer treatment is a big battlefield for virosome-based drug delivery systems. This review provides an overview of the general concept, preparation procedures, working mechanisms, preclinical studies and clinical applications of virosomes in cancer treatment.

References

1. I. M. Verma and M. D. Weitzman, Gene therapy: twenty-first century medicine, Annu. Rev. Biochem. 74 (2005) 711-738; DOI: 10.1146/annurev.biochem.74.050304.091637.10.1146/annurev.biochem.74.050304.091637
Search in Google Scholar
2. C. Baum, A. Schamba ch, J. Bohne and M. Galla, Retrovirus vectors: toward the plentivirus? Mol. Ther. 13 (2006) 1050-1063; DOI: 10.1016/j.ymthe.2006.03.007.10.1016/j.ymthe.2006.03.007
Search in Google Scholar
3. C. Li, D. E. Bowles, T. van Dyke and R. J. Samulski, Adeno-associated virus vectors: potential applications for cancer gene therapy, Cancer Gene Ther. 12 (2005) 913-925; DOI: 10.1038/sj.cgt.7700876.10.1038/sj.cgt.7700876
Search in Google Scholar
4. L. S. Young, P. F. Se arle, D. Onion and V. Mautner, Viral gene therapy strategies: from basic science to clinical application, J. Pathol. 208 (2006) 299-318; DOI: 10.1002/path.1896.10.1002/path.1896
Search in Google Scholar
5. R. Wattiaux, N. Lauren t, S. Wa_ iaux-De Coninck and M. Jadot, Endosomes, lysosomes: their implication in gene transfer, Adv. Drug Deliv. Rev. 41 (2000) 201-208.10.1016/S0169-409X(99)00066-6
Search in Google Scholar
6. M. S. Al-Dosari and X. Gao, Nonviral gene delivery: principle, limitations, and recent progress, AAPS J. 11 (2009) 671-681; DOI: 10.1208/s12248-009-9143-y.10.1208/s12248-009-9143-y278207719834816
Search in Google Scholar
7. M. Morille, C. Passirani , A. Vonarbourg, A. Clavreul and J. P. Benoit, Progress in developing cationic vectors for non-viral systemic gene therapy against cancer, Biomaterials 29 (2008) 3477-3496; DOI: 10.1016/j.biomaterials.2008.04.036.10.1016/j.biomaterials.2008.04.03618499247
Search in Google Scholar
8. Y. Kaneda and Y. Tabata, Non-viral vectors for cancer therapy, Cancer Sci. 97 (2006) 348-354; DOI: 10.1111/j.1349-7006.2006.00189.x.10.1111/j.1349-7006.2006.00189.x16630130
Search in Google Scholar
9. J. Zabner, A. J. Fasbender , T. Moninger, K. A. Poellinger and M. J. Welsh, Cellular and molecular barriers to gene transfer by a cationic lipid, J. Biol. Chem. 270 (1995) 18997-9007.10.1074/jbc.270.32.189977642560
Search in Google Scholar
10. I. A. Schaap, F. Eghiaian, A. des Georges and C. Veigel, Effect of envelope proteins on the mechanical properties of influenza virus, J. Biol. Chem. 287 (2012) 41078-41088; DOI: 10.1074/jbc. M112.412726.10.1074/jbc
Search in Google Scholar
11. C. Moser, M. Muller, M. D. Kaeser, U. Weydemann and M. Amacker, Influenza virosomes as vaccine adjuvant and carrier system, Expert Rev. Vaccines 12 (2013) 779-791; DOI: 10.1586/14760584.2013.811195.10.1586/14760584.2013.811195
Search in Google Scholar
12. D. Koppers-Lalic, M. M. Hoge nboom, J. M. Middeldorp and D. M. Pegtel, Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine, Adv. Drug Deliv. Rev. 65 (2013) 348-356; DOI: 10.1016/j.addr.2012.07.006.10.1016/j.addr.2012.07.006
Search in Google Scholar
13. J. D. Almeida, D. C. Edwards, C. M. Brand and T. D. Heath, Formation of virosomes from influenza subunits and liposomes, Lancet 2 (1975) 899-901. 10.1016/S0140-6736(75)92130-3
Search in Google Scholar
14. R. K. Scheule, Novel preparati on of functional Sindbis virosomes, Biochemistry 25 (1986) 4223-4232.10.1021/bi00363a009
Search in Google Scholar
15. W. A. Petri, Jr. and R. R. Wagn er, Reconstitution into liposomes of the glycoprotein of vesicular stomatitis virus by detergent dialysis, J. Biol. Chem. 254 (1979) 4313-4316.10.1016/S0021-9258(17)30004-2
Search in Google Scholar
16. K. Metsikko, G. van Meer and K. Simons, Reconstitution of the fusogenic activity of vesicular stomatitis virus, EMBO J. 5 (1986) 3429-3435.10.1002/j.1460-2075.1986.tb04665.x
Search in Google Scholar
17. A. Helenius, E. Fries and J. Kart enbeck, Reconstitution of Semliki forest virus membrane, J. Cell Biol. 75 (1977) 866-880.10.1083/jcb.75.3.866
Search in Google Scholar
18. A. Helenius, M. Sarvas and K. Simo ns, Asymmetric and symmetric membrane reconstitution by detergent elimination: Studies with Semliki-Forest-virus spike glycoprotein and penicillinase from the membrane of Bacillus licheniformis, Eur. J. Biochem. 116 (1981) 27-35.
Search in Google Scholar
19. T. Uchida, J. Kim, M. Yamaizumi, Y. Miyake and Y. Okada, Reconstitution of lipid vesicles associated with HVJ (Sendai virus) sikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin, J. Cell Biol. 80 (1979) 10-20.10.1083/jcb.80.1.10
Search in Google Scholar
20. S. Bagai, A. Puri, R. Blumenthal and D. P. Sarkar, Hemagglutinin-neuraminidase enhances F protein-mediated membrane fusion of reconstituted Sendai virus envelopes with cells, J. Virol. 67 (1993) 3312-3318.10.1128/jvi.67.6.3312-3318.1993
Search in Google Scholar
21. A. Vainstein, M. Hershkovitz, S. Isra el, S. Rabin and A. Loyter, A new method for reconstitution of highly fusogenic Sendai virus envelopes, Biochim. Biophys. Acta 773 (1984) 181-188.10.1016/0005-2736(84)90081-6
Search in Google Scholar
22. A. Jamali, M. Holtrop, A. de Haan, H. Hashemi, M. Shenagari, A. Memarnejadian, F. Roohvand, F. Sabahi, M. T. Kheiri and A. Huckriede, Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination, Immunol. Lett . 148 (2012) 77-82; DOI: 10.1016/j.imlet. 2012.08.006.
Search in Google Scholar
23. S. G. Reed, S. Bertholet, R. N. Coler a nd M. Friede, New horizons in adjuvants for vaccine development, Trends Immunol. 30 (2009) 23-32; DOI: 10.1016/j.it.2008.09.006.10.1016/j.it.2008.09.00619059004
Search in Google Scholar
24. J. J. Skehel and D. C. Wiley, Receptor b inding and membrane fusion in virus entry: the influenza hemagglutinin, Annu. Rev. Biochem. 69 (2000) 531-569; DOI: 10.1146/annurev.biochem.69.1.531.10.1146/annurev.biochem.69.1.53110966468
Search in Google Scholar
25. M. Ohuchi, N. Asaoka, T. Sakai and R. Ohu chi, Roles of neuraminidase in the initial stage of influenza virus infection, Microbes Infect. 8 (2006) 1287-1293; DOI: 10.1016/j.micinf.2005.12.008.10.1016/j.micinf.2005.12.00816682242
Search in Google Scholar
26. R. Wagner, M. Matrosovich and H. D. Klenk , Functional balance between haemagglutinin and neuraminidase in influenza virus infections, Rev. Med. Virol. 12 (2002) 159-166; DOI: 10.1002/ rmv.352.10.1002/rmv.35211987141
Search in Google Scholar
27. T. Nakajima, Novel gene transfer systems: i ntelligent gene transfer vectors for gene medicines, Curr. Top. Med. Chem. 12 (2012) 1594-1602.
Search in Google Scholar
28. T. Stegmann, H. W. Morselt, F. P. Booy, J. F . van Breemen, G. Scherphof and J. Wilschut, Functional reconstitution of influenza virus envelopes, EMBO J. 6 (1987) 2651-2659.10.1002/j.1460-2075.1987.tb02556.x
Search in Google Scholar
29. M. G. Cusi, Applications of influenza virosom es as a delivery system, Hum. Vaccin. 2 (2006) 1-7.10.4161/hv.2.1.249417012895
Search in Google Scholar
30. E. Soussan, S. Cassel, M. Blanzat and I. Rico- La_ es, Drug delivery by so_ ma_ er: matrix and vesicular carriers, Angew. Chem. Int. Ed. Engl. 48 (2009) 274-288; DOI: 10.1002/anie.200802453.10.1002/anie.20080245319072808
Search in Google Scholar
31. G. V. Radha, T. S. Rani and B. Sarvani, A revie w on proniosomal drug delivery system for targeted drug action, J. Basic Clin. Pharm. 4 (2013) 42-48; DOI: 10.4103/0976-0105.113609.10.4103/0976-0105.113609397926324808669
Search in Google Scholar
32. H. I. Chang and M. K. Yeh, Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy, Int. J. Nanomedicine 7 (2012) 49-60; DOI: 10.2147/Ĳ N.S26766.
Search in Google Scholar
33. A. K. Dey and I. K. Srivastava, Novel adjuvants a nd delivery systems for enhancing immune responses induced by immunogens, Expert Rev. Vaccines 10 (2011) 227-251; DOI: 10.1586/erv.10.142.10.1586/erv.10.14221105782
Search in Google Scholar
34. M. L. De Temmerman, J. Rejman, J. Demeester, D. J. Irvine, B. Gander and S. C. De Smedt, Particulate vaccines: on the quest for optimal delivery and immune response, Drug Discov. Today 16 (2011) 569-582; DOI: 10.1016/j.drudis.2011.04.006. 10.1016/j.drudis.2011.04.00621570475
Search in Google Scholar
35. A. Huckriede, L. Bungener, T. Stegmann, T. Daemen, J. Medema, A. M. Palache and J. Wilschut, The virosome concept for influenza vaccines, Vaccine 23 (Suppl. 1) (2005) S26-S38; DOI: 10.1016/j. vaccine.2005.04.026.
Search in Google Scholar
36. A. M. Harandi and D. Medaglini, Mucosal adjuvants, C urr. HIV Res. 8 (2010) 330-335.10.2174/157016210791208695
Search in Google Scholar
37. I. Jabbal-Gill, Nasal vaccine innovation, J. Drug Tar get. 18 (2010) 771-786; DOI: 10.3109/ 1061186X.2010.523790.10.3109/1061186X.2010.523790
Search in Google Scholar
38. S. Beg, A. Samad, I. Nazish, R. Sultana, M. Rahman, M. Z. Ahmad and M. Akbar, Colloidal drug delivery systems in vaccine delivery, Curr. Drug Targets 14 (2013) 123-137.10.2174/138945013804806523
Search in Google Scholar
39. S. M. Moghimi and J. Szebeni, Stealth liposomes and lon g circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res. 42 (2003) 463-478.
Search in Google Scholar
40. E. Waelti, N. Wegmann, R. Schwaninger, A. Wetterwald, C. Wingenfeld, B. Rothen-Rutishauser and C. D. Gimmi, Targeting her-2/neu with antirat Neu virosomes for cancer therapy, Cancer Res. 62 (2002) 437-444.
Search in Google Scholar
41. E. Mastrobattista, P. Schoen, J. Wilschut, D. J. Crommeli n and G. Storm, Targeting influenza virosomes to ovarian carcinoma cells, FEBS Lett. 509 (2001) 71-76.10.1016/S0014-5793(01)03112-X
Search in Google Scholar
42. J. Liu, J. Wu, B. Wang, S. Zeng, F. Qi, C. Lu, Y. Kimura a nd B. Liu, Oral vaccination with a liposomeencapsulated influenza DNA vaccine protects mice against respiratory challenge infection, J. Med. Virol. 86 (2014) 886-894; DOI: 10.1002/jmv.23768.10.1002/jmv.23768
Search in Google Scholar
43. J. de Jonge, J. M. Leenhouts, M. Holtrop, P. Schoen, P. Sch errer, P. R. Cullis, J. Wilschut and A. Huckriede, Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA, Biochem. J. 405 (2007) 41-49; DOI: 10.1042/BJ20061756.10.1042/BJ20061756
Search in Google Scholar
44. J. de Jonge, M. Holtrop, J. Wilschut and A. Huckriede, Recon stituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs, Gene Ther. 13 (2006) 400-411; DOI: 10.1038/sj.gt.3302673.10.1038/sj.gt.3302673
Search in Google Scholar
45. L. Bungener, K. Serre, L. Bĳ l, L. Leserman, J. Wilschut, T. Daemen and P. Machy, Virosome-mediated delivery of protein antigens to dendritic cells, Vaccine 20 (2002) 2287-2295.10.1016/S0264-410X(02)00103-2
Search in Google Scholar
46. P. Schoen, A. Chonn, P. R. Cullis, J. Wilschut and P. Scherrer , Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles, Gene Ther. 6 (1999) 823-832; DOI: 10.1038/sj.gt.3300919.10.1038/sj.gt.330091910505107
Search in Google Scholar
47. R. Bron, A. Ortiz and J. Wilschut, Cellular cytoplasmic delive ry of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes), Biochemistry 33 (1994) 9110-9117.10.1021/bi00197a0138049214
Search in Google Scholar
48. L. Bungener, A. Huckriede, A. de Mare, J. de Vries-Idema, J. Wil schut and T. Daemen, Virosomemediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity, Vaccine 23 (2005) 1232-1241; DOI: 10.1016/j.vaccine.2004.09.002.10.1016/j.vaccine.2004.09.002
Search in Google Scholar
49. A. Arkema, A. Huckriede, P. Schoen, J. Wilschut and T. Daemen, In duction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes, Vaccine 18 (2000) 1327-1333.10.1016/S0264-410X(99)00404-1
Search in Google Scholar
50. Y. Kaneda, Virosomes: evolution of the liposome as a targeted drug delivery system, Adv. Drug Deliv. Rev. 43 (2000) 197-205.
Search in Google Scholar
51. N. Nakamura, D. A. Hart, C. B. Frank, L. L. Marchuk, N. G. Shrive, N. Ota, K. Taira, H. Yoshikawa and Y. Kaneda, Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition, J. Biochem. 129 (2001) 755-759.10.1093/oxfordjournals.jbchem.a00291611328598
Search in Google Scholar
52. Y. Krishnamachari, S. M. Geary, C. D. Lemke, and A. K. Salem, Nanopa rticle delivery systems in cancer vaccines, Pharm. Res. 28 (2011) 215-236; DOI: 10.1007/s11095-010-0241-4.10.1007/s11095-010-0241-4355924320721603
Search in Google Scholar
53. T. Stegmann, T. Kamphuis, T. Meĳ erhof, E. Goud, A. de Haan and J. Wi lschut, Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation, Vaccine 28 (2010) 5543-5550; DOI: 10.1016/j.vaccine.2010.06.041. 10.1016/j.vaccine.2010.06.04120600502
Search in Google Scholar
54. M. Shafique, J. Wilschut and A. de Haan, Induction of mucosal and syst emic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands, Vaccine 30 (2012) 597-606; DOI: 10.1016/j.vaccine.2011.11.054.10.1016/j.vaccine.2011.11.05422120195
Search in Google Scholar
55. R. J. Cox, G. Pedersen, A. S. Madhun, S. Svindland, M. Saevik, L. Break well, K. Hoschler, M. Willemsen, L. Campitelli, J. K. Nostbakken, G. J. Weverling, J. Klap, K. C. McCullough, M. Zambon, R. Kompier and H. Sjursen, Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial, Vaccine 29 (2011) 8049-8059; DOI: 10.1016/j.vaccine.2011.08.042.10.1016/j.vaccine.2011.08.04221864624
Search in Google Scholar
56. M. D. Joshi, W. J. Unger, G. Storm, Y. van Kooyk and E. Mastrobattista, Targeting tumor antigens to dendritic cells using particulate carriers, J. Control. Release 161 (2012) 25-37; DOI: 10.1016/j.jconrel. 2012.05.010.
Search in Google Scholar
57. D. Felnerova, J. F. Viret, R. Gluck and C. Moser, Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs, Curr. Opin. Biotech. 15 (2004) 518-529; DOI: 10.1016/j.copbio. 2004.10.005.
Search in Google Scholar
58. G. Leroux-Roels, Unmet needs in modern vaccinology: adjuvants to improve t he immune response, Vaccine 28 (Suppl. 3) (2010) C25-C36; DOI: 10.1016/j.vaccine.2010.07.021.10.1016/j.vaccine.2010.07.02120713254
Search in Google Scholar
59. P. Nordly, H. B. Madsen, H. M. Nielsen and C. Foged, Status and future pros pects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators, Expert Opin. Drug Deliv. 6 (2009) 657-672; DOI: 10.1517/17425240903018863.10.1517/1742524090301886319538037
Search in Google Scholar
60. P. G. Cech, T. Aebi, M. S. Abdallah, M. Mpina, E. B. Machunda, N. Westerfeld , S. A. Stoffel, R. Zurbriggen, G. Pluschke, M. Tanner, C. Daubenberger, B. Genton and S. Abdulla, Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: Randomized phase 1b trial in semi-immune adults & children, PLoS One 6 (2011) e22273; DOI: 10.1371/journal. pone.0022273.
Search in Google Scholar
61. A. Cassone and A. Casadevall, Recent progress in vaccines against fungal dis eases, Curr. Opin. Microbiol. 15 (2012) 427-433; DOI: 10.1016/j.mib.2012.04.004.10.1016/j.mib.2012.04.004342435222564747
Search in Google Scholar
62. J. Torresi, D. Johnson and H. Wedemeyer, Progress in the development of prev entive and therapeutic vaccines for hepatitis C virus, J. Hepatol. 54 (2011) 1273-1285; DOI: 10.1016/j.jhep.2010.09.040.10.1016/j.jhep.2010.09.04021236312
Search in Google Scholar
63. I. Naldi, M. Taranta, L. Gherardini, G. Pelosi, F. Viglione, S. Grimaldi, L. P ani and C. Cinti, Novel epigenetic target therapy for prostate cancer: a preclinical study, PLoS One 9 (2014) e98101; DOI: 10.1371/journal.pone.0098101.10.1371/journal.pone.0098101403113724851905
Search in Google Scholar
64. R. M. Roy and B. S. Klein, Dendritic cells in antifungal immunity and vaccine design, Cell Host Microbe 11 (2012) 436-446; DOI: 10.1016/j.chom.2012.04.005.10.1016/j.chom.2012.04.005340196522607797
Search in Google Scholar
65. A. Huckriede, L. Bungener, W. ter Veer, M. Holtrop, T. Daemen, A. M. Palache and J. Wilschut, Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity, Vaccine 21 (2003) 925-931.
Search in Google Scholar
66. E. Nardin, The past decade in malaria synthetic peptide vaccine clinical trials, Hum. Vaccin. 6 (2010) 27-38.10.4161/hv.6.1.960120173408
Search in Google Scholar
67. J. Wilschut, Influenza vaccines: the virosome concept, Immunol. Lett. 122 (2009) 118-121; DOI: 10.1016/j.imlet.2008.11.006.10.1016/j.imlet.2008.11.00619100779
Search in Google Scholar
68. C. Hatz, R. van der Ploeg, B. R. Beck, G. Frosner, M. Hunt and C. Herzog, Successf ul memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years, Clin. Vaccine Immunol. 18 (2011) 885-887; DOI: 10.1128/CVI.00358-10.10.1128/CVI.00358-10312252821411599
Search in Google Scholar
69. W. Z. Zhou, D. S. Hoon, S. K. Huang, S. Fujii, K. Hashimoto, R. Morishita, and Y. K aneda, RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization, Hum. Gene Ther. 10 (1999) 2719-2724; DOI: 10.1089/10430349950016762.10.1089/1043034995001676210566900
Search in Google Scholar
70. M. G. Cusi, M. T. Del Vecchio, C. Terrosi, G. G. Savellini, G. Di Genova, M. La Plac a, F. Fallarino, C. Moser, C. Cardone, G. Giorgi, G. Francini and P. Correale, Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine, J. Immunol. 174 (2005) 7210-7216. 10.4049/jimmunol.174.11.721015905566
Search in Google Scholar
71. P. Correale, M. T. Del Vecchio, T. Renieri, G. Di Genova, M. La Placa, C. Remondo, G. G. Savellini, C. Terrosi, R. Zurbriggen, M. Amacker, G. Francini and M. G. Cusi, Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine, Cancer Lett. 263 (2008) 291-301; DOI: 10.1016/j.canlet.2008.01.018.10.1016/j.canlet.2008.01.01818291576
Search in Google Scholar
72. U. Wiedermann, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer, R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner and C. C. Zielinski, A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study, Breast Cancer Res. Treat. 119 (2010) 673-683.10.1007/s10549-009-0666-920092022
Search in Google Scholar
73. R. Schwaninger, E. Waelti, P. Zajac, A. Wetterwald, D. Mueller and C. D. Gimmi, Virosom es as new carrier system for cancer vaccines, Cancer Immunol. Immunother. 53 (2004) 1005-17; DOI: 10.1007/ s00262-004-0545-5.10.1007/s00262-004-0545-515185010
Search in Google Scholar
74. L. Bungener, A. de Mare, J. de Vries-Idema, P. Sehr, A. van der Zee, J. Wilschut and T. Daemen, A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease, Antivir. Ther. 11 (2006) 717-727.10.1177/135965350601100616
Search in Google Scholar
75. M. Walczak, A. de Mare, A. Riezebos-Brilman, J. Regts, B. N. Hoogeboom, J. T. Visser, M. Fiedler, P. Jansen-Durr, A. G. van der Zee, H. W. Nĳ man, J. Wilschut and T. Daemen, Heterologous primeboost immunizations with a virosomal and an alphavirus replicon vaccine, Mol. Pharm. 8 (2011) 65-77; DOI: 10.1021/mp1002043.10.1021/mp100204320825215
Search in Google Scholar
76. M. Adamina, R. Schumacher, P. Zajac, W. P. Weber, R. Rosenthal, C. Groeper, C. Feder, R. Z urbriggen, M. Amacker, G. C. Spagnoli, D. Oertli and M. Heberer, Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy, J. Liposome Res. 16 (2006) 195-204; DOI: 10.1080/ 08982100600848546.10.1080/0898210060084854616952874
Search in Google Scholar
77. R. Schumacher, M. Amacker, D. Neuhaus, R. Rosenthal, C. Groeper, M. Heberer, G. C. Spagnoli , R. Zurbriggen and M. Adamina, Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro, Vaccine 23 (2005) 5572-5582; DOI: 10.1016/j.vaccine.2005.07.099.10.1016/j.vaccine.2005.07.09916165256
Search in Google Scholar
78. M. K. Zakaria, I. Khan, P. Mani, P. Chattopadhyay, D. P. Sarkar and S. Sinha, Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells, BMC Cancer 14 (2014) 582; DOI: 10.1186/1471-2407-14-582.10.1186/1471-2407-14-582415391125108398
Search in Google Scholar
79. Y. Nishimura, H. Mieda, J. Ishii, C. Ogino, T. Fujiwara and A. Kondo, Targeting cancer cell- specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes, J. Nanobiotechnol. 11 (2013) 19; DOI: 10.1186/1477-3155-11-19.10.1186/1477-3155-11-19369938023800313
Search in Google Scholar
80. C. Cinti, M. Taranta, I. Naldi and S. Grimaldi, Newly engineered magnetic erythrocytes for s ustained and targeted delivery of anti-cancer therapeutic compounds, PLoS One 6 (2011) e17132; DOI: 10.1371/journal.pone.0017132.10.1371/journal.pone.0017132304415421373641
Search in Google Scholar
81. M. Kurooka and Y. Kaneda, Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells, Cancer Res. 67 (2007) 227-236; DOI: 10.1158/ 0008-5472.CAN-06-1615.10.1158/0008-5472.CAN-06-161517210703
Search in Google Scholar
82. A. Fujihara, M. Kurooka, T. Miki and Y. Kaneda, Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation, Cancer Immunol. Immunother. 57 (2008) 73-84; DOI: 10.1007/s00262-007-0351-y.10.1007/s00262-007-0351-y17602226
Search in Google Scholar
83. M. Tanaka, T. Shimbo, Y. Kikuchi, M. Matsuda and Y. Kaneda, Sterile alpha motif containing dom ain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon, Int. J. Cancer. 126 (2010) 1982-1991; DOI: 10.1002/ĳ c.24965.10.1002/ijc.2496519830690
Search in Google Scholar
84. Y. Kawaguchi, Y. Miyamoto, T. Inoue and Y. Kaneda, Efficient eradication of hormone-resistant h uman prostate cancers by inactivated Sendai virus particle, Int. J. Cancer 124 (2009) 2478-2487; DOI: 10.1002/ĳ c.24234.10.1002/ijc.2423419173282
Search in Google Scholar